Published in Masui on January 01, 2015
The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J (2003) 3.10
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med (2004) 2.50
Nociceptors are interleukin-1beta sensors. J Neurosci (2008) 2.26
Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care (2012) 2.02
A randomized trial of ultrasound image-based skin surface marking versus real-time ultrasound-guided internal jugular vein catheterization in infants. Anesthesiology (2007) 2.01
Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU. Crit Care Med (2004) 1.79
Dexmedetomidine sedation in children after cardiac surgery. Pediatr Crit Care Med (2010) 1.75
Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis (2002) 1.61
Fructose administration increases intraoperative core temperature by augmenting both metabolic rate and the vasoconstriction threshold. Anesthesiology (2006) 1.50
Ultrasound-guided radial artery catheterization in infants and small children. Pediatr Crit Care Med (2013) 1.49
Surfactant proteins A and D enhance pulmonary clearance of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol (2006) 1.45
CXC chemokines and their receptors are expressed in type II cells and upregulated following lung injury. Am J Respir Cell Mol Biol (2003) 1.44
Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med (2006) 1.42
Mechanically ventilated children with 2009 pandemic influenza A/H1N1: results from the National Pediatric Intensive Care Registry in Japan. Pediatr Crit Care Med (2012) 1.42
IV Immunoglobulin for Acute Lung Injury and Bacteremia in Pseudomonas aeruginosa Pneumonia. Crit Care Med (2016) 1.41
Phosphodiesterase 3 inhibition reduces platelet activation and monocyte tissue factor expression in knee arthroplasty patients. Anesthesiology (2009) 1.39
Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol (2010) 1.38
Prediction of pediatric endotracheal tube size by ultrasonography. Anesthesiology (2010) 1.34
Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther (2006) 1.30
Roles of oxidants and redox signaling in the pathogenesis of acute respiratory distress syndrome. Antioxid Redox Signal (2008) 1.28
Injury and repair in lung and airways. Crit Care Med (2003) 1.28
TLR4 signaling is essential for survival in acute lung injury induced by virulent Pseudomonas aeruginosa secreting type III secretory toxins. Respir Res (2004) 1.19
Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain (2010) 1.17
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol (2013) 1.14
Bradykinin enhances AMPA and NMDA receptor activity in spinal cord dorsal horn neurons by activating multiple kinases to produce pain hypersensitivity. J Neurosci (2008) 1.13
Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model. J Immune Based Ther Vaccines (2003) 1.11
Bradykinin produces pain hypersensitivity by potentiating spinal cord glutamatergic synaptic transmission. J Neurosci (2005) 1.10
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol (2011) 1.09
Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol (2006) 1.07
Respiratory rate criteria for pediatric systematic inflammatory response syndrome. Pediatr Crit Care Med (2014) 1.07
Exploring Causative Pathology Is Essential for Validating Harmful Effects of Late Intubation. Crit Care Med (2016) 1.06
O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa. J Clin Microbiol (2003) 1.05
An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun (2008) 1.03
Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats. Basic Clin Pharmacol Toxicol (2008) 1.03
Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns (2005) 1.02
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci (2012) 1.00
Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU. Biochem Biophys Res Commun (2004) 0.98
Effects of controlled perioperative antimicrobial prophylaxis on infectious outcomes in pediatric cardiac surgery. Crit Care Med (2007) 0.97
Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review. Crit Care (2014) 0.96
Ultrasound evidence of the optimal wrist position for radial artery cannulation. Can J Anaesth (2009) 0.95
Protein binding between PcrG-PcrV and PcrH-PopB/PopD encoded by the pcrGVH-popBD operon of the Pseudomonas aeruginosa type III secretion system. Infect Immun (2003) 0.95
Application of fluorescent cholangiography to single-incision laparoscopic cholecystectomy. Surg Endosc (2011) 0.94
Single-nucleotide-polymorphism mapping of the Pseudomonas aeruginosa type III secretion toxins for development of a diagnostic multiplex PCR system. J Clin Microbiol (2003) 0.93
Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. Eur J Pharmacol (2010) 0.93
Acute lung inflammation and ventilator-induced lung injury caused by ATP via the P2Y receptors: an experimental study. Respir Res (2008) 0.91
Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice. Eur J Pharmacol (2011) 0.91
Peripheral inflammation induces up-regulation of TRPV2 expression in rat DRG. Pain (2005) 0.91
Effects of Cl2MDP-encapsulating liposomes in a murine model of Pseudomonas aeruginosa-induced sepsis. J Liposome Res (2002) 0.91
Does cooling really improve outcomes in patients with septic shock? Am J Respir Crit Care Med (2013) 0.89
Supplemental parenteral nutrition in critically ill patients. Lancet (2013) 0.88
C/EBPβ is involved in the amplification of early granulocyte precursors during candidemia-induced "emergency" granulopoiesis. J Immunol (2012) 0.88
A role of androgen receptor protein in cell growth of an androgen-independent prostate cancer cell line. Biosci Biotechnol Biochem (2005) 0.87
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol (2014) 0.87
AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun (2010) 0.87
Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sci (2011) 0.86
Neutrophil elastase activity in acute lung injury and respiratory distress syndrome. Respirology (2008) 0.85
Pharmacokinetics of glycopeptide antibiotics in children. J Infect Chemother (2012) 0.85
[Anaphylaxis during anesthesia--especially from neuromuscular blocking agents]. Masui (2011) 0.85
Fluorescence navigation hepatectomy by visualization of localized cholestasis from bile duct tumor infiltration. J Am Coll Surg (2010) 0.84
Joint statement on mechanical circulatory support in children: a consensus review from the Pediatric Cardiac Intensive Care Society and Extracorporeal Life Support Organization. Pediatr Crit Care Med (2013) 0.84
Effects of high glucose on AVP-induced hyperplasia, hypertrophy, and type IV collagen synthesis in cultured rat mesangial cells. Endocr Res (2012) 0.83
Peripheral sensitization caused by insulin-like growth factor 1 contributes to pain hypersensitivity after tissue injury. Pain (2011) 0.83
Dysregulation of lung injury and repair in moesin-deficient mice treated with intratracheal bleomycin. Am J Physiol Lung Cell Mol Physiol (2008) 0.83
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res (2006) 0.83
Neonatal electroencephalography shows low sensitivity to anesthesia. Neurosci Lett (2012) 0.82
A novel method for ultrasound-guided radial arterial catheterization in pediatric patients. Anesth Analg (2014) 0.82
Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. J Pharmacol Exp Ther (2013) 0.82
Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. Metabolism (2009) 0.82
Vasopressin induces human mesangial cell growth via induction of vascular endothelial growth factor secretion. Neuropeptides (2010) 0.81
Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Microbiol Immunol (2009) 0.81
Perioperative management of aplastic anemia in pregnancy with platelet transfusion refractoriness. Can J Anaesth (2007) 0.81
V-antigen genotype and phenotype analyses of clinical isolates of Pseudomonas aeruginosa. J Clin Microbiol (2004) 0.81
Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells. Pharmacol Res (2008) 0.81
Cloning and characterization of a novel GRP78-binding protein in the rat brain. J Biol Chem (2003) 0.81
Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochem Biophys Res Commun (2010) 0.81
Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem Biophys Res Commun (2010) 0.80
Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.80
Fas ligand released by activated monocytes causes apoptosis of lung epithelial cells in human acute lung injury model in vitro. Biol Pharm Bull (2008) 0.80
Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist. Vascul Pharmacol (2005) 0.80
Perioperative amino acid infusion improves recovery and shortens the duration of hospitalization after off-pump coronary artery bypass grafting. Anesth Analg (2006) 0.80
Depletion of phagocytes in the reticuloendothelial system causes increased inflammation and mortality in rabbits with Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol (2008) 0.80
Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.80